| Vol. 7.31 – 20 August, 2021 |
| |
|
|
| Researchers showed that dietary fructose improved the survival of intestinal cells and increased intestinal villus length in several mouse models. In hypoxic intestinal cells, fructose 1-phosphate inhibited the M2 isoform of pyruvate kinase to promote cell survival. [Nature] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| A combination of single-cell transcriptomic profiling, in silico lineage tracing from methylation, open chromatin and somatic mutation analyses, and functional studies in organoid models showed that Barrett’s esophagus originated from gastric cardia through c-MYC and HNF4A-driven transcriptional programs. [Science] |
|
|
|
| Scientists identified that colorectal cancer manifested with altered ILC3s that were characterized by reduced frequencies, increased plasticity, and an imbalance with T cells. [Cell] |
|
|
|
| Visceral adipose-derived factors promoted vasculogenesis and the onset of metastatic dissemination by activation of STAT3, which inhibited miR-200a and enhanced ZEB2 expression, effectively reprogramming colorectal cancer cells into a highly metastatic phenotype. [Nature Communications] |
|
|
|
| Investigators explored the inhibitory role of ITLN1 in the tumor-permissive microenvironment that existed during the first occurrence and subsequent development of colorectal carcinoma. [Oncogene] |
|
|
|
| The authors demonstrated that mutations in the adenomatous polyposis coli (APC) gene led to colonic epithelial cell resistance to CD8+ T cell cytotoxicity by induction of PD-L1 expression. [Oncogene] |
|
|
|
| Through transcriptomics analysis, researchers observed that Entamoeba histolytica infection was associated with increased expression of IL-33 mRNA in both the human and murine colon. [Mucosal Immunology] |
|
|
|
| Scientists created three different types of chimeric MrNV VLPs that had specificity toward the epidermal growth factor receptor (EGFR), a cancer cell biomarker, by incorporating the EGFR-specific GE11 peptide at three different locations within the host cell recognition site of the capsid. [Scientific Reports] |
|
|
|
| Investigators showed a comprehensive transcriptome-wide characterization of mouse gut organoids derived from different intestinal compartments and from mice of different gender and age. [Scientific Reports] |
|
|
|
| Researchers demonstrated that NDRG2 promoted the differentiation of colorectal cancers, potentially through the inhibition of aerobic glycolysis via TXNIP induction. [Digestive Diseases and Sciences] |
|
|
|
| The authors explored the use of prime editing in human organoids. Common TP53 mutations could be correctly modeled in human adult stem cell–derived colonic organoids with efficiencies up to 25% and up to 97% in hepatocyte organoids. [Life Science Alliance] |
|
|
|
| Scientists treated human colon cancer oxaliplatin-resistant cells with oxaliplatin combined with natural product erianin, evaluated the impact of erianin on drug resistance, and explored the relationship between erianin- related oxaliplatin resistance and JAK2/STAT3 signaling pathway in vitro. [Cell Biology International] |
|
|
|
| Researchers presented a comprehensive multi-omic analysis of malignant ascitic fluid samples and their corresponding tumor cell lines from 98 patients, including whole-genome sequencing, RNA sequencing, DNA methylation and enhancer landscape. [Nature Cancer] |
|
|
|
|
| Scientists provide a critical overview of both clinical and preclinical advances using tumor organoids. [Cancer Cell] |
|
|
|
|
| STEMCELL Technologies and Hubrecht Organoid Technology announced that they have signed an agreement for the use of tissue-derived organoids—including lung, intestinal, and liver organoids—for use in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL. [STEMCELL Technologies, Inc.] |
|
|
|
| Gracell Biotechnologies, Inc. announced an exclusive license agreement with FutureGen Biopharm to develop engineered immune cell therapies targeting Claudin 18.2, a tumor-specific marker that is overexpressed in a variety of tumor tissues, including in gastric or gastroesophageal junction cancers. [Gracell Biotechnologies, Inc.] |
|
|
|
|
| October 12 – 14, 2021 Carlsbad, California, United States and Virtual |
|
|
|
|
|
| Purdue University – West Lafayette, Indiana, United States |
|
|
|
| National Institute of Allergy and Infectious Diseases – Bethesda, Maryland, United States |
|
|
|
| Amgen – San Francisco, California, United States |
|
|
|
| The Scripps Research Institute – La Jolla, California, United States |
|
|
|
| Philipps University of Marburg – Marburg, Germany |
|
|
|
|